Bibliography
- FITZGERALD DJ, ROY L, CATELLA F, FITZGERALD GA: Platelet activation in unstable coronary disease. New Engl. J. Med. (1986) 315:983–989.
- FUSTER V, STEELE PM, CHESEBRO JH: Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J. Am. Coll. Cardiol. (1985) 5:175B–184B.
- ASHBY B, DANIEL JL, SMITH JB: Mechanisms of platelet activation and inhibition. Platelet Health Dis. (1990) 4(1):1–26.
- STEERING COMMITTEE OF THE PHYSICIANS' HEALTH STUDY RESEARCH GROUP: Final Report on the aspirin component of the ongoing physicians' health study. New Engl. J. Med. (1989) 321:129–135.
- •The pivotal study showing the benefit of aspirin in primary prevention of MI.
- ROTH GJ, MAJERUS PW: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J. Clin. Invest. (1975) 56:264–260.
- FITZGERALD GA: Modern drug therapy: dipyridamole. New Engl. J. Med. (1987) 316:1247–1257.
- BUCKLER P, DOUGLAS AS: Antithrombotic treatment. Br. Med. J. (1983) 287:196–198.
- SALTIEL E, WARD A: Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs (1987) 34:222–262.
- CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet (1996) 348(9038):1329–1339.
- EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet GPIIb/IIIa receptor in high-risk coronary angioplasty. New Engl. J. Med. (1994) 330:956–961.
- ••The first clinical result demonstrating GPIIb/IIIa blockade.
- PRISM-PLUS STUDY INVESTIGATORS: Inhibition of the platelet GPIIb/IIIa receptor with tirofiban in unstable angina and non-Q -wave myocardial infarction. New Engl. J. Med. (1998) 338:1488–1497.
- THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet GPIIb/IIIa with eptifibatide in patients with acute coronary syndromes. New Engl. J. Med. (1998) 339:436–443.
- VORCHHEIMER DA, FUSTER V: Oral platelet GPIIb/IIIa receptor antagonists: the present challenge is safety. Circulation (1998) 97:312–314.
- ••A concise review of key issues in the development of GPIIb/IIIa antagonists.
- THE TIMI 12 INVESTIGATORS: Randomized trial of an oral platelet GPIIb/IIIa antagonist, Sibrafiban, in patients after an acute coronary syndrome, results of the TIMI 12 Trial. Circulation (1998) 97:340–349.
- SIMPENDORFER C, KOTTKE-MARCHANT K, LOWRIE M, et al.: First chronic platelet GPIIb/IIIa Integrin blockade: a randomized placebo-controlled pilot study of Xemilofiban in unstable angina with percutaneous coronary interventions. Circulation (1997) 96:76–81.
- FOX JE, LIPFERT L, CLARK EA, et al.: The role of the platelet membrane skeleton in mediating signal transduction. Association of GP IIb/IIIa, pp60c-src, pp62c-yes and the p2 lras GTPase-activating protein with the membrane skeleton. J. Bio. Chem. (1993) 268(34):25973–25984.
- MOUSA SA, BOZARTH JM, LORELLI W, et al.: Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagoinst: comparative platelet binding profiles with c7E3. J. Pharm. Exp. Ther. (1998) 286:1277–1284.
- •Description of a novel class of oral non-peptide GPIIb/IIIa antagonists.